Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 5,000 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 5,000 shares of the company’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $10.92, for a total value of $54,600.00. Following the sale, the director now owns 806,283 shares of the company’s stock, valued at approximately $8,804,610.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Cyrus Harmon also recently made the following trade(s):

• On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.51, for a total transaction of $142,650.00.
• On Thursday, March 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $10.97, for a total transaction of $219,400.00.
• On Thursday, February 29th, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $12.41, for a total transaction of $310,250.00.

Olema Pharmaceuticals Price Performance

Shares of NASDAQ OLMA opened at $11.24 on Wednesday. The stock has a market capitalization of $628.65 million, a PE ratio of -5.20 and a beta of 2.10. Olema Pharmaceuticals, Inc. has a one year low of $5.02 and a one year high of $17.79. The business’s fifty day moving average price is $11.44 and its 200-day moving average price is $12.84.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Monday, March 11th. The company reported ($0.49) EPS for the quarter, meeting the consensus estimate of ($0.49). As a group, equities analysts expect that Olema Pharmaceuticals, Inc. will post -2.34 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on OLMA. Citigroup assumed coverage on shares of Olema Pharmaceuticals in a research report on Tuesday, January 30th. They set a “buy” rating and a $20.00 target price on the stock. Capital One Financial reissued an “overweight” rating on shares of Olema Pharmaceuticals in a research report on Thursday, February 22nd. Finally, The Goldman Sachs Group started coverage on Olema Pharmaceuticals in a research report on Tuesday, April 2nd. They set a “buy” rating and a $24.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $21.43.

Institutional Trading of Olema Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio bought a new stake in Olema Pharmaceuticals during the 3rd quarter valued at $35,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Olema Pharmaceuticals during the 4th quarter valued at $89,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Olema Pharmaceuticals in the 4th quarter worth about $130,000. SG Americas Securities LLC purchased a new position in Olema Pharmaceuticals during the 3rd quarter valued at about $142,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in shares of Olema Pharmaceuticals during the third quarter valued at about $164,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.